Noninvasive prenatal Screening
NIPS (NIPT) to meet clinical and patient needs
Every pregnancy is unique, and you make choices about patient care based on both your clinical judgment and your patients' perspectives. So offering a choice of screening options is important.
Backed by science and clinical validation, over a decade of NIPS testing experience, and knowledge and insight from millions of tests, Labcorp offers different panels to meet the needs of your patients and your practice. You have the option of core NIPS for Trisomy 21, 18 and 13, as well as optional insights for fetal sex, sex chromosome aneuploidies, clinically relevant microdeletions and additional trisomies. We also offer a clinically validated genome-wide screen.
Consistent with good practice guidelines, Labcorp is here to support you and your patients with educational materials about what the screening includes, what results may mean and the importance of diagnostic testing for confirmation. We also offer genetic counseling and access to clinical and scientific experts
NIPS(NIPT) options
The only clinically validated genome-wide NIPS (NIPT), screens all 23 chromosome pairs, reporting aneuploidies, large deletions and duplications greater than 7 Mb in addition to select microdeletions; after more than 35,000 tests resulted, more than 29% of all positive findings were only detectable using genome-wide cfDNA, the methodology used by MaterniT GENOME, as compared to traditional NIPS.1
The pioneering NIPS (NIPT) with more than 1 million tests run; screens the core trisomies 21, 18, and 13, and (optionally) fetal sex, clinically relevant microdeletions, sex chromosome aneuploidies, and trisomies 16 and 22.
| MaterniT® GENOME | MaterniT®21 PLUS | |
|---|---|---|
| Detects trisomy 21 (Down syndrome) | Yes | Yes |
| Detects trisomy 18 (Edwards syndrome) | Yes | Yes |
| Detects trisomy 13 (Patau syndrome) | Yes | Yes |
| Detects sex chromosome abnormalities* | Yes | Yes |
| Reports fetal fraction | Yes | Yes |
| Reports fetal sex* | Yes | Yes |
| Multiple gestations† | Yes | |
| Detects additional trisomies 22, 16* | Yes | Yes |
| Detects select microdeletions, such as 22q11.2 (DiGeorge syndrome)** | Yes | Yes |
| Performed as early as 9 weeks | Yes | Yes |
| ~5 calendar day turnaround time | Yes | Yes |
| Genome-wide analysis of all chromosomes | Yes | |
| Reports on any trisomy or monosomy | Yes | |
| Detects subchromosomal abnormalities ≥ 7 Mb | Yes | |
* Optional reporting ** Optional reporting for MaterniT 21 PLUS
MaterniT specimen collection kit
Starting in July 2023, we are updating our MaterniT cfDNA specimen collection kits with a new look to help increase understanding that MaterniT is a screening test. The kit components and specimen collection requirements will not change.
Additional Resources
Understanding Costs
Use our cost estimator get an immediate estimate for most tests we offer based on your specific insurance plan (so have your policy number handy).
Understand Your Results
If you have already had a test, we can answer questions about your results.
Genetic Counseling
Genetic counselors translate and communicate genetic information into practical, understandable terms.